Is fosfomycin appropriate for treating an Enterobacter cloacae urinary tract infection, and what dosing regimen should be used?

Fosfomycin for Enterobacter cloacae UTI

Fosfomycin is not recommended for Enterobacter cloacae urinary tract infections due to poor intrinsic activity, high baseline resistance rates, and rapid emergence of resistance during therapy. 1, 2

Why Fosfomycin Fails Against Enterobacter cloacae

Intrinsic Poor Activity

• Enterobacter cloacae demonstrates significantly higher fosfomycin MICs compared to E. coli, with MIC50 values of 16 mg/L and MIC90 values of 128 mg/L for ceftazidime-nonsusceptible strains, far exceeding the therapeutic threshold. 3
• In dynamic bladder infection models simulating actual urinary concentrations, E. cloacae isolates with MICs >16 mg/L were not reliably killed despite achieving therapeutic urinary drug levels. 1
• Only 38% of Klebsiella pneumoniae isolates (a closely related Enterobacterales species) were susceptible to fosfomycin, suggesting similar poor activity across this bacterial family. 4

High Baseline Resistance

• Fosfomycin resistance genes (fosA, fosA3, fosA4) are frequently detected in E. cloacae, with 65% carrying fosA, 20% carrying fosA3, and 15% carrying fosA4 among resistant isolates. 2
• Baseline heteroresistance (high-level resistant subpopulations present before drug exposure) was detected in 50% of E. cloacae isolates tested, predicting treatment failure regardless of drug exposure. 5

Rapid Resistance Emergence

• Significant rises in fosfomycin MIC occur during therapy, with total population MIC50 increasing from 4 to 64 mg/L and resistant subpopulation MIC50 rising from 128 to >1024 mg/L after exposure. 1
• Among 24 Enterobacteriaceae isolates tested in dynamic models, 15 of 24 (63%) regrew during therapy, with E. cloacae showing particularly poor outcomes. 1

FDA-Approved Indication Excludes Enterobacter

• The FDA label for oral fosfomycin explicitly limits its indication to uncomplicated cystitis caused by E. coli and Enterococcus faecalis only—Enterobacter species are not included. 6
• The label specifically states fosfomycin is not indicated for pyelonephritis or complicated infections, and if bacteriuria persists or reappears, other therapeutic agents should be selected. 6

Alternative Treatment Options for E. cloacae UTI

For Complicated UTI Due to Multidrug-Resistant E. cloacae

• Ceftazidime-avibactam 2.5 g IV every 8 hours is recommended for complicated UTI caused by carbapenem-resistant Enterobacterales (weak recommendation, very low quality evidence). 7
• Meropenem-vaborbactam 4 g IV every 8 hours or imipenem-cilastatin-relebactam 1.25 g IV every 6 hours are alternative options for CRE-associated complicated UTI. 7
• Single-dose aminoglycoside (amikacin or gentamicin) is recommended for simple cystitis due to CRE, with amikacin showing 38.2% susceptibility against CRE in Taiwan surveillance data. 7

For Simple Cystitis Due to Susceptible E. cloacae

• Nitrofurantoin 100 mg twice daily for 5-7 days remains a first-line option if the isolate is susceptible and the infection is limited to the lower urinary tract. 8
• Fluoroquinolones (ciprofloxacin or levofloxacin) for 3 days if local resistance rates are <10% and susceptibility is confirmed. 8

Critical Clinical Pitfalls

Do Not Use Fosfomycin If:

• The pathogen is Enterobacter cloacae, Klebsiella pneumoniae, or other non-E. coli Enterobacterales, as clinical and microbiological failure rates are unacceptably high. 1, 4
• The infection involves the upper urinary tract (pyelonephritis), as fosfomycin achieves inadequate tissue concentrations outside the bladder. 9, 6
• Susceptibility testing shows MIC >16 mg/L, which predicts treatment failure even with adequate urinary concentrations. 1
• The patient is male, as efficacy data derive almost exclusively from female cohorts and outcomes are inferior. 9

Testing Limitations

• Routine susceptibility testing for fosfomycin is often unavailable in clinical laboratories, and when performed, commercial methods (VITEK®2, ETEST®) overestimate MICs and resistance for Enterobacter species, failing to meet ISO performance criteria. 10
• A disk diffusion zone <24 mm is a better predictor of baseline heteroresistance and treatment failure than standard MIC breakpoints. 5

Summary Algorithm

1. Identify the pathogen: If E. cloacae is isolated from urine culture, do not use fosfomycin. 6, 1
2. Assess infection severity: If simple cystitis with susceptible organism, use nitrofurantoin or fluoroquinolone; if complicated UTI or CRE, use IV beta-lactam/beta-lactamase inhibitor combination. 7, 9
3. Check susceptibility: If fosfomycin MIC >16 mg/L or disk zone <24 mm, select alternative therapy. 5, 1
4. Avoid fosfomycin for upper tract disease, male patients, or when Enterobacter/Klebsiella species are involved. 9, 6, 1